An influential review that is due out tomorrow will not contain up-to-date efficacy information about Tamiflu, the widely used influenza drug sold by Roche, because researchers at the Cochrane Collaboration say they were stymied by the drugmaker in their efforts to fully assess the medication, according to reports. Iain Chalmers, one of the founders of the Cochrane Collaboration, a non-profit group dedicated to analyzing medical evidence, last week told a conference on research integrity in London that a review of influenza treatments will state that Roche would not comply with requests to provide additional data, Nature writes.
